S

Sage Therapeutics
D

SAGE

7.37500
USD
-0.41
(-5.27%)
مغلق
حجم التداول
0
الربح لكل سهم
-4
العائد الربحي
-
P/E
-1
حجم السوق
453,421,984
أصول ذات صلة
A
ACAD
-0.495
(-2.98%)
16.115 USD
ALNY
ALNY
-4.62
(-1.73%)
262.41 USD
B
BLUE
-0.16000
(-3.17%)
4.88000 USD
C
CRSP
-1.550
(-4.53%)
32.650 USD
INCY
INCY
0.180
(0.29%)
62.500 USD
I
IONS
-0.210
(-0.73%)
28.505 USD
O
OPK
-0.00500
(-0.32%)
1.57500 USD
REGN
REGN
-14.36
(-2.30%)
610.88 USD
VRTX
VRTX
0.63
(0.13%)
484.01 USD
المزيد
الأخبار المقالات

العنوان: Sage Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.